Page Title
Drug Development Pipeline
Back to the Drug Development Pipeline
Fosfomycin/Tobramycin Inhalation Solution (FTI)
Status
Phase TwoTherapeutic Approach
Anti-Infective
Fosfomycin/tobramycin inhalation solution (FTI) is a combination antibiotic consisting of fosfomycin and tobramycin. FTI has shown increased effectiveness against bacteria compared to fosfomycin or tobramycin alone.
Status
A phase 2b study to test the safety and effectiveness of FTI is planned.
Sponsor
This program is sponsored by CURx Pharmaceuticals. It is being conducted within the Therapeutics Development Network.
Recent Fosfomycin/Tobramycin Inhalation Solution (FTI) Studies
-
Completed with Results
Inhaled Fosfomycin/Tobramycin for People with CF and P. aeruginosa (Gilead GS-US-207-0103)
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More